🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06185621
Recruiting Not applicable

The Effect of Aspirin on Recurrent Acute Pancreatitis

NCT06185621 · tracked via the Priya Life Science China tracker
Sponsor
Air Force Military Medical University, China
Phase
Not applicable
Started
2023-11-01
Last updated
2023-12-29

Condition(s) studied

Recurrent Acute PancreatitisPreventionAspirin

Investigational drug(s) / intervention(s)

100mg aspirin

100mg aspirin: Patients received oral 100mg aspirin, one tablet daily for 2 years

Study summary

Recurrent acute pancreatitis (RAP) was defined as two or more occurrences of acute pancreatitis, which was associated with higher percentages of morbidities and mortalities, lower patients' life quality and increased health-care costs. Current interventions, including cholecystectomy and abstain from drinking were reported to be effective methods for preventing the recurrences of biliary and alcoholic etiologies, respectively. However, there were no effective preventions for other etiologies, such as idiopathic etiologies. Non-steroid anti-inflammatory drugs (NSAIDs), including indomethacin, diclofenac and aspirin could inhibiting the inflammatory cascade of pancreatitis. In this study, we aimed at exploring the effects of 100mg aspirin on reducing the occurrences of recurrent acute pancreatitis.

Eligibility

Sex
ALL
Min age
14 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Patients with with recurrent acute pancreatitis Exclusion Criteria: * Less than 2 episodes of acute pancreatitis in the past year * Latrogenic AP (pancreatitis due to endoscopic retrograde cholangiopancreatography, surgery, or after other invasive treatment). Iatrogenic pancreatitis will not count as an episode of recurrent pancreatitis * Previous allergy to Non-Steroid Anti-inflammatory Drugs (NSAIDs) * Regularly taking aspirin or other NSAIDs \>3 doses per week * Contradictions for the medications of NSAIDs, including Active peptic ulcer disease or gastrointestinal hemorrhage within 3 months or previous peptic ulcer, history of significant hepatic or renal disease, platelet count less than 100X10\^9/L or international normalized ratio (INR) \>1.5) * Biliary stones * Receiving endoscopic sphincterotomy and/or pancreatic stent placement and/or cholecystectomy and/or pancreatic surgery after the latest pancreatitis or planning to undergo one of those interventions within preceding 2 years * Patients with the level of serum triglycerides of \>5.65 mmol/L and did not receive regular lipid-lowering therapy * Primary hyperparathyroidism has been well-treated after last episode of pancreatitis and recruitment or will be operated in \<2 years * Patients with previously heavy alcohol consumption (50g/day for men, 40g/day for women) and have not quit drinking, or have significant withdrawal symptoms * Pregnant or breastfeeding patients * Inability to give informed consents

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Air Force Military Medical University, China Xi'an Shaanxi Recruiting

More Air Force Military Medical University, China trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06185621 on ClinicalTrials.gov ↗ ← All trials in China